RefleXion Medical awarded SBIR Phase I grant from the National Cancer Institute (NCI)

September 27, 2011

Burlingame, CA (September 27, 2011) – RefleXion Medical Inc. announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase I grant from the National Cancer Institute (NCI). During the twelve-month project, entitled “Real-time PET guided radiation therapy for cancer treatment”, RefleXion will collaborate with Dr. Ted Graves, Assistant Professor of Radiation Physics at Stanford University, to further develop RefleXion’s novel and patented PET-radiotherapy system for cancer treatment.

“The SBIR Phase I award from the National Cancer Institute is important support and validation for the development of RefleXion’s PET-guided radiation therapy system,” said Samuel Mazin, the Principal Investigator on the grant and President of RefleXion.  “We are also extremely excited to collaborate with Dr. Graves at the Stanford Cancer Institute, a leading researcher at one of the world’s premier institutions in oncology research and radiation therapy technology innovation.”

“The RefleXion system will enable radiation targeting based on functional and biological characteristics of a tumor at the time of treatment, while accounting for motion of the target. This could offer significant clinical benefits for cancer patients,” said Dr. Graves, “I am thrilled to be collaborating with Dr. Mazin and other researchers at RefleXion.”

“Personalized radiotherapy has long been desired as a tool for clinicians to improve efficacy. RefleXion’s novel approach to leveraging Positron Emission Tomography during radiation therapy treatment could deliver on this promise,” said Dr. John C. Ford, a 40 year industry veteran who is a seed investor in RefleXion and former Senior Vice President, and Senior Scientist, at Varian Medical Systems.

About RefleXion Medical

RefleXion Medical is a privately held medical device company developing the first biologically-guided radiation therapy system for cancer treatment.  By leveraging Positron Emission Tomography (PET) in a novel way, RefleXion’s patented technology will allow tumors to continuously signal their location during treatment. For more information, visit

Contact Information

Akshay Nanduri

RefleXion Business Development